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Objective. To determine the prevalence of Vitamin D (VitD) deficiency/insufficiency in mothers of preterm neonates less than or
equal to 32 weeks of gestation and determine if the current level of VitD supplementation used for preterm neonates is appropriate.
Design. Prospective study from 10th May 2015 to 1st November 2016. Setting. Neonatal Intensive Care Unit at the Canberra Hospital.
Patients. Mothers and their preterm neonates born less than or equal to 32 weeks gestation. Interventions. Maternal VitD levels
were obtained within 3-4 days following delivery. Neonatal VitD levels were obtained in the first 3-4 days of life, at 3-4 weeks
of age, and at 6-8 weeks of age. Demographic data and data on VitD intake from parenteral nutrition, enteral feeds, and vitamin
supplementation agents were collected.Results. 70 neonates were enrolled into the study.Median gestationwas 29 (27-30) weeks and
median birth weight 1197 (971.2-1512.5) grams. Median maternal VitD level was 54.5 (36-70.7) nmol/L, median neonatal Vit D level
at birth was 57 (42-70) nmol/L. Median Vit D level at 3 weeks and 6 weeks were 63.5 nmol/L (53-80.2) nmol/L and 103 (71.5-144)
nmol/L respectively. 22/55 (40%) mothers were VitD deficient/insufficient. 25/70 (36%) neonates were VitD deficient/insufficient
at birth. Of those neonates who were VitD deficient/insufficient at birth 5/25(10%) were deficient/insufficient at 6 weeks. The
median intake of VitD at 6 weeks was 826.5 (577.5-939.5) IU/day. Conclusions. VitD deficiency/insufficiency in mothers of preterm
neonates and in preterm neonates at birth is common. Routine screening of maternal VitD and their preterm neonates along with
individualized supplementation regimens in mothers and preterm infants may optimize VitD status and reduce risk of ongoing
VitD deficiency/insufficiency.
1. Introduction
Vitamin D (VitD) deficiency has significant health impacts
particularly related to calcium and bone metabolism. Sig-
nificant calcium deposition in the fetal skeleton occurs in
utero during the third trimester; thus preterm infants are
at risk of osteopenia [1], which can predispose to fractures
[2]. Approximately 10-20% of preterm infants <1000g have
radiographically defined rickets [3]. Optimizing calcium and
phosphorus intake should prevent osteopenia of prematurity
in majority of cases [4] but requires sufficient levels of VitD.
In addition to bone and calcium related issues resulting from
severe deficiency, VitD deficiency has also been linked to
an increased risk of diabetes mellitus, certain cancers, and
autoimmune diseases [5]. VitD receptors thus are thought to
have multiple functions, many of which have not yet been
fully elucidated, including roles in regulating genes that are
involved in cell growth, immune function, and cardiovascular
health. Given the widespread biologic effects of VitD it
is reasonable to postulate that VitD deficiency in humans
during the fetal and neonatal period may have long lasting
health consequences [6].
Maternal Vit D deficiency has been shown to be detri-
mental to the fetus with increased risk of intrauterine growth
restriction, preeclampsia, gestational diabetes mellitus, and
pretermbirth, all of which can have significant health impacts
on the fetus and neonate [7, 8]. Studies have also shown
that low cord blood levels of VitD were associated with an
increased risk of respiratory infection during the first few
months of life and increased risk of recurrent wheeze in
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early childhood [9]. Animal studies have demonstrated that
VitD is likely to be important in lung development, with
offspring of deficient mothers having reduced lung volumes
and function [10]; the importance of this for pretermneonates
is paramount given their already high risk of chronic lung
disease. The potential long-term public health impact of
preventing VitD deficiency, particularly during this critical
time, is becoming increasingly evident.
Studies have shown 11-19% of neonates in Australia
and New Zealand have levels <25nmol/L [11, 12]. A New
Zealand study showed that 46% of pregnant women had
Vitamin D levels <50nmol/l [13]. Studies also show that
up to 18% of pregnant women in predominantly Caucasian
populations had VitD levels <50nmol/L [11, 14, 15]. However,
the implications to the fetus of maternal VitD deficiency are
not yet fully understood and more research is required.
There is no worldwide consensus on the recommended
daily requirements for VitD for preterm infants. In theUnited
States a recommended daily intake for VLBW infants is
200 to 400IU [16] and the European Society for Paediatrics
Gastroenterology, Hepatology, and Nutrition recommends
800-1000 IU [17]. Studies in preterm neonates have shown
that supplementation with amounts from 400- 3000 IU/day
is safe. Several studies have shown that supplementing with
standard levels of VitD may be insufficient for some preterm
neonates [12, 18].
The aims of this study were to determine (1) the preva-
lence of VitD deficiency in mothers of preterm neonates and
(2) if the current level ofVitD supplementation is appropriate.
2. Methods
This is a prospective cohort study carried out in a single
Neonatal Intensive Care Unit (NICU) at The Centenary
Hospital for Women and Children, ACT from 10th May 2015
to 1st November 2016.
Inclusion criteria were mothers and their preterm
neonates born less than or equal to 32 weeks gestation and
admitted to the NICU. Neonates were excluded if they had
significant chromosomal or congenital anomalies. Mothers
and their babies were recruited and consented in the first 72
hours postdelivery.Maternal data collected included whether
there was antenatal VitD supplementation, ethnicity and
season of birth. Standard variables including sex, gestational
age, and weight were recorded.
Maternal 25(OH) D3 was measured in the immediate
postnatal period (day 1-4). Enrolled neonates had their
25(OH)D3 levels measured during the first 3 days of life, at 3-
4weeks, and 6-8weeks of age. Neonatal serum calcium, phos-
phorus, and alkaline phosphatasewere collected at the time of
VitD collection. 25(OH) D3 was measured using the Liaison
 25 OH vitamin D immunoassay. The definitions of VitD
deficiency used for this study were deficiency <30nmol/L,
insufficiency 30-49nmol/L, and sufficiency ≥ 50nmol/L.
Neonates were supplemented with VitD as per depart-
mental guidelines - 160IU/day when on TPN with lipids; 800
IU/day from 7 days or when on full feeds from Pentavite;
120IU/100ml preterm formula; 120IU/100ml human milk
fortification and 25IU/L in maternal breast milk. The daily
amount of VitD supplementation was estimated for the
first 8 weeks of life from neonatal fluid and medication
charts. This was estimated from the combined intake of
pentavite (400IU/0.45ml), TPN with lipids, formula, human
milk fortifier, and breast milk. The amount received by each
preterm neonate varied throughout their NICU stay and
depended on feeding regimen and fluid intake.
During the early part of the study period (after 14 patients
had had their 6-8 weeks VitD level measured) it was noted
that 50% of neonates had VitD levels >150nmol/L, with an
average level of 152nmol/L for all subjects at that time point.
While there had been no evidence of adverse effects of high
VitD levels, the routine supplementation dose of pentavite
was reduced from 800 IU to 400 IU daily.
Data were stored and analysed using IBM SPSS statistics
version 22 (SPSS: An IBM Company. Chicago Ill, USA,
2010). Data will be presented as number and percentage with
odds ratio and 95% confidence interval (CI) or median and
interquartile ranges.
This study was approved by the ACT Health Human
Research Ethics Committee.
3. Results
Seventy premature neonates were enrolled in the study. The
median (IQR) gestational age was 29 (27-30) weeks and birth
weight was 1197.5 (971.2-1512.5) grams. Majority of neonates
(70%) were enrolled during the autumn-winter period and
Caucasians formed the major ethnic group comprising 71.4%
of the cohort with 8.5% of neonates being of Aboriginal
descent. Demographic characteristics are shown in Table 1.
3.1. Maternal Vitamin D Status. Of the 70 neonates enrolled
in the study, maternal serum VitD level in the immediate
postnatal period was available for 55 mothers, therefore only
these were included for analysis of VitD status in mothers.
The median (IQR) VitD level at delivery was 54.5 (36-70.7)
nmol/L. VitD deficiency was noted in 18.2% of mothers,
21.8% had VitD insufficiency, and 60% had sufficient VitD
levels (Table 2). Thirty (55%) of the 55 mothers were on
VitD supplementation. The prevalence of Vit D insuffi-
ciency/deficiency in women receiving supplementation was
30%.The percentage insufficient/ deficient was higher at 52%
in the nonsupplemented group (p=0.11). The levels of Vit
D in mothers who received supplementation was 58.0 (22-
176) nmol/L which was significantly higher than mothers
who did not receive supplementation, 41.0 (20-86) nmol/L,
(p=0.04). The prevalence of VitD insufficiency/deficiency
amongst Caucasian mothers was 34% as compared to 53%
in non-Caucasian mothers (p=0.24). Fifty-three percent
of non-Caucasian mothers received VitD supplementation
compared to 55% Caucasian mothers (p=1.0).
3.2. Vitamin D and Bone Markers in Preterm Neonates. 25
(OH) D3 and bone markers were available for all 70 neonates
within the first 3 days of life. This data was available for
60 neonates at 3-4 weeks and for 49 neonates at 6-8 weeks.
The decrease in available results was predominantly due to
transfer to other hospitals for convalescent care. The median
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Table 1: Demographic characteristics.
Characteristics All neonates (n=70)
Male n (%) 50 (71.4)
Gestational age, weeks∗ 29(27-30)
Birth weight in grams∗ 1197.5(971.2-1512.5)
Ethnicity, n (%)
Caucasian 50(71.4)
Aboriginal 6(8.5)
African 4(5.7)
Eurasian 3(4.3)
South American 3(4.3)
Indian 2(2.9)
Asian 2(2.9)
Season at birth, n (%)
Summer-spring 21(30)
Autumn-Winter 49(70)
∗Values are median (IQR).
Table 2: Maternal vitamin D status in the immediate postnatal period.
Number (Total 55) Percentage (%)
Sufficient (≥50nmol/L) 33 60
Insufficiency (30-49nmol/L) 12 21.8
Deficiency (<30nmol/L) 10 18.2
(IQR) VitD level within the first 3 days of life was 57 (42-70)
nmol/L, which increased to 63.5 (53-80.2) nmol/L between 3
and 4 weeks and to 103 (71.5-144) nmol/L between 6 and 8
weeks (Figure 1). Serum levels of VitD and bone markers at
these three-time frames are shown in Table 3.
The prevalence of VitD insufficiency at birth was 30%;
which decreased to 15% at 3-4 weeks and to 10.2% at 6-
8 weeks (p=0.001). Also, a reduction in the prevalence of
VitD deficiency was seen from 5.7% at birth to 1.7% at 3-4
weeks to none at 6-8 weeks (Table 4). Overall, the combined
prevalence of VitD insufficiency/deficiency at birth was 36%,
which decreased to 17% at 3-4 weeks (p=0.02) and further
to 10% at 6-8weeks (p=0.002). All of the neonates who were
insufficient at 6-8 weeks were insufficient/deficient at birth.
The number of babies who had sufficient VitD levels was
significantly higher at 3-4 weeks (p-=0.02) and 6-8 weeks
(p=0.002) compared to birth levels. There was no significant
difference in sufficiency at 3-4 weeks compared to 6-8 weeks
(p=0.41).There was a positive correlation betweenVitD levels
at birth and 3-4weeks (r=0.374, p=0.003) but not between
birth and 6-8 weeks (r=0.248, p=0.086). There was a strong
correlation between VitD levels at 3-4 weeks and 6-8 weeks
(r=0.632, p<0.001).
Low serum maternal VitD was associated with a higher
likelihood of VitD insufficiency/deficiency in neonates at
birth (p<0.001) and at 3-4 weeks (p=0.006) but not
at 6-8 weeks (p=0.14). The prevalence of VitD insuffi-
ciency/deficiency in preterm infants whose mothers did not
receive VitD supplementation was 44% as opposed to 37%
in infants whose mothers received Vit D supplementation
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Figure 1: SerumVitaminD (25 (OH)D3) levels of preterm neonates
at different time frames. Values of serum vitamin D are expressed in
nmol/L.
(p=0.60). Thus, there was no difference in neonatal birth
VitD levels in relation to maternal supplementation during
pregnancy alone. However, there was a strong positive corre-
lation between maternal VitD levels and preterm VitD levels
at birth, r=0.622 (Figure 2).
Neonates of non-Caucasian descent were more likely
to be VitD insufficiency/deficiency compared to Caucasian
neonates (65% versus 24% (p=0.002)). However, no asso-
ciation was observed between VitD status and sex, season
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Table 3: Serum bone markers in preterm neonates.
1-3 days 3-4 weeks 6-8 weeks
25 (OH) D3,nmol/L 57 (42-70) 63.5 (53-80.2) 103 (71.5-144)
Calcium, mmol/L 2.42 (2.16-2.53) 2.72 (2.63-2.77) 2.68 (2.63-2.73)
Phosphate, mmol/L 1.90 (1.63-2.17) 2.15 (1.86-2.29) 2.10 (1.87-2.29)
ALKP, IU/L 219 (164-268) 331 (270-439) 324 (256-376)
Values are expressed as median (IQR). ALKP: alkaline phosphatase.
Table 4: Vitamin D deficiency status at different time intervals.
1-3 days 3-4 weeks 6-8 weeks P Value
N=70 (%) N=60 (%) N=49 (%)
Sufficiency 45 (64.3) 50(83.3) 44(89.8) 0.667
(≥50nmol/L)
Insufficiency 21 (30.0) 9(15) 5(10.2) 0.001
(30-49nmol/L)
Deficiency 4(5.7) 1(1.7) - 0.18
(<30nmol/L)
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Figure 2: Correlation of Maternal Vitamin D levels and Preterm
Vitamin D levels at birth.
of birth, gestational age, and birth weight. Comparison of
incidence of sepsis and necrotizing enterocolitis with VitD
status at birth also showed no significance (Table 5).
Subgroup analysis comparing the prevalence of VitD
deficiency amongst premature neonates receiving high dose
pentavite (800 IU/day of VitD) against those receiving low
dose pentavite (400 IU/day of VitD) showed that, at 6-8
weeks, the prevalence of VitD insufficiency was 7.1% in the
high dose group as compared to 11.4% in the low dose group
(p=0.65). The median serum VitD level in the high dose
group at 3-4 weeks was 61(49.5-100.5) nmol/L, similar to
that in the low dose group 64 (53.7-76.7) nmol/L. However,
at 6-8 weeks, the high dose group had a higher VitD level
[126 (69.2-182.2) nmol/L] compared to the low dose group
[96 (73-131) nmol/L], p=0.25. The differences between serum
bone markers-calcium, phosphate, and alkaline phosphatase
were not statistically different in the high and low dose group
(Table 6).
3.3. Vitamin D Intake in Preterm Neonates. The majority of
preterm neonates between 3-4 weeks and 6-8 weeks of age
were breast fed, 60% (n=42) and 57.1% (n=44) respectively.
The median VitD intake at 3-4 weeks increased from 749.5
(554.2-861) IU/day to 826.5 (577.5-939.5) IU/day at 6-8 weeks
(p=0.06). At 3-4weeks the median VitD intake in sufficient
group was 761.5 (604.5-866.7) IU/day which was signifi-
cantly higher as compared to insufficient/deficient group,
618 (197.2-755.7) IU/day (p=0.04). However, at 6-8weeks
the median VitD intake in sufficient group as compared to
insufficient/deficient group was not statistically significant,
p=0.22.
4. Discussion
This study shows that maternal VitD status has implications
on VitD status of preterm neonates at birth and at 3-4 weeks
post birth. Our study indicates that current dosing regimens
of VitD may not be adequate for some neonates and that
VitD levels should be performed on all preterm neonates at
3-4 weeks of life. In addition, VitD levels at birth correlated
with those at 3-4 weeks. Hence, we suggest that VitD levels
should be performed in all high risk VLBW neonates - those
born to non-Caucasians or to mothers with VitD deficiency.
Our recommendation of targeting a higher dose of VitD in
deficient babies is similar to that suggested by Fort et al [21].
In our cohort maternal VitD level was insufficient/
deficient in 40% of mothers, despite the fact that 55% of
the mothers were supplemented with VitD. This was slightly
higher than in the population study done by Perampalam et
al. where 35% of pregnant women had 25(OH) D3 less than
50nmol/L [22]. This may be due to the fact that majority
of our cohort were enrolled in winter/spring. In our study,
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Table 5: Factors associated with vitamin D status at different time points in preterm infants.
Variable
Vitamin D insuffi-
ciency/deficiency (p
value)
Low serummaternal vit D P<0.001∗
(<50nmol/L) P=0.006#
Ethnicity 0.003##
Season-Winter/Autumn 0.954
GA 0.382∗
Birth weight 0.646∗
Male sex 0.986∗
Sepsis 0.500∗
NEC 0.838∗
∗p value at birth, #p value at 3-4 weeks, ##non-Caucasian. Sepsis definition (CDC definition): a neonate was considered to have a BSI if there was (1) a definite
pathogen in blood culture OR (2) growth of a possible contaminant (e.g., coagulase-negative staphylococcus, CONS) in blood PLUS treatment with antibiotics
≥96 h (or death<96 h) PLUS. Growth of the same organism on repeat cultureOR one ormore abnormal laboratorymarkers (e.g., C-reactive protein>10 mg/L,
immature: total neutrophil ratio >0.2) (definite infection) OR clinical features consistent with systemic infection (e.g., lethargy, apnoea, and significant change
in respiratory condition) (clinical infection) [19, 20].
Table 6: Serum bone markers in high dose group and low dose group at 6-8weeks.
High dose group Low dose group P value
N=14 N=35
25 (OH) D3,nmol/L 126(69.2-182.2) 96 (73-131) 0.25
Calcium, mmol/L 2.68 (2.5-3.0) 2.68(2.3-2.9) 0.99
Phosphate, mmol/L 2.05(1.4-2.2) 2.13(1.0-2.5) 0.46
ALKP, IU/L 328(211-851) 310 (132-853) 0.33
Values are expressed as median (IQR). ALKP: alkaline phosphatase.
maternal VitD supplementation did not have a significant
influence in reducing maternal VitD insufficiency/deficiency
as well as in preterm infant VitD status.This can be explained
by the fact that the amount ofmaternal VitD supplementation
and compliance to treatment were unknown. Our study
showed that low maternal VitD level was associated with
significantly higher deficiency in neonates at birth and at 3-4
weeks.There was positive correlation betweenmaternal VitD
levels at birth and preterm VitD at birth. Similar findings
have also been reported in previous studies [12, 13, 23].
The prevalence of VitD deficiency in preterm infants was
also higher in the non-Caucasian population in our cohort
(p=0.003), similar to the findings of Monangi et al. [12]. In
non-Caucasians melanin decreases the amount of ultraviolet
B radiation reaching the basal skin layer to generate the
production of cholecalciferol (Vitamin D3) [24]. Metanalysis
done by Qin et al found that pregnant women with VitD
levels<50nmol/L experienced a significantly increased risk of
preterm birth [25]. The Australian clinical practice guideline
on antenatal care does not currently recommend routine
screening of VitD levels; however, risk-based screening is
common in clinical practice.
Epidemiological surveys from Australia and New
Zealand have shown that 40-57% of neonates have
VitD levels <50nmol/L [9, 11]. The prevalence of VitD
insufficiency/deficiency in our study at birth was 35.7%;
which decreased to 7.1% at the time of discharge with
our current supplementation regimen. There is no clear
consensus at present as to what exact level of vitamin
D constitutes sufficiency in terms of biologic and health
effects at any age, particularly neonatal, and ranges from
50-80nmol/L are most often quoted [26, 27]. There was
positive correlation between VitD levels at birth and at
3-4weeks. Previous research has demonstrated that VitD
levels in preterm or low birth weight babies rise rapidly
during the first 1-2 weeks of VitD supplementation (with
1000-3000IU) and then plateau around 82nmol/ml after 7
weeks, suggesting that this is a healthy neonatal level [1, 28].
Our data was in agreement to this and the median level
of VitD increased from 57nmol/L during the first week to
103nmol/L between 6 and 8 weeks.
At the beginning of our study, high levels of VitD
(>150nmol/L) as well as hypercalcemia (serum calcium >
2.5mmol/L) was observed in 50% of neonates (7 out of 14
babies) at 6-8 weeks. In view of these results, pentavite sup-
plementation was ceased in all 7 neonates. All these neonates
were receiving VitD supplementation at 800IU/day. The
amount of breast milk fortification, calcium and phosphate
supplementation remained the same both during 800IU/day
and 400 IU/day of Vit D supplementation as per our unit
protocol. Furthermore, median phosphate and ALKP levels
were similar in both the groups suggesting hypercalcemiawas
due to high Vit D levels rather than hypophosphatemia. High
VitD levels can cause increased calcium absorption from
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the intestines resulting in hypercalcemia and hypercalciuria
leading to polyuria, dehydration, poor growth, and extra-
skeletal calcification especially nephrocalcinosis. Therefore,
reviewing VitD levels in preterm neonates with hypercal-
cemia on VitD supplementation can become important to
guide supplementation dosage. The calcium levels normal-
ized in all 7 babies following cessation of pentavite. As such,
we did not perform renal ultrasound prior to discharge for
nephrocalcinosis. Levels of serum VitD being high at 6-8
weeks have been reported in studies by Fort et al. [19] and
Tergestina et al. [29]. There was no significant increase in
Vit D deficiency in our cohort following dose reduction;
whichmightmean that a daily supplementation of 400IU/day
should be adequate to obtain a sufficient vitamin D level.
Fort et al. suggested that higher dosing for the first 1-2 weeks
of life to get VitD levels into the normal range followed
by lower dosages may be more appropriate to prevent high
serum levels of VitD occurring [21]. However, no adverse
effects were seen in a trial with higher neonatal VitD levels
[29].
VitD status of preterm infants is entirely dependent on
extrinsic supplementation as VitD synthesis from sunlight
is lacking. The recommendations for VitD supplementation
vary widely between different NICUs’ from 400IU to 1000IU
[8, 9] and the current trend of fortification of breast milk
provides additional VitD depending on individual unit pro-
tocol. Most of our neonates were receiving fortified breast
milk which contains calcium as well as phosphate along with
additional VitD supplementation in the form of Pentavite.
The median VitD intake in our preterm cohort increased
following supplementation from 749.5 (554.2-861) IU/day at
3-4 weeks to 826.5(577.5-939.5) IU/day at 6-8 weeks. The
lower VitD intake in the high dose group at 6-8 weeks
as compared to low dose group was secondary to cessa-
tion of VitD supplementation following high serum levels
(>150nmol/L) of VitD at 3-4 weeks, thus emphasizing that
perhaps screening at 3-4 weeks should be done so as to adjust
VitD dosage.
The limitation of our study was that it was not powered
to assess clinical outcomes such as sepsis, necrotizing entero-
colitis, chronic lung disease, and growth and developmental
outcomes. The amount of maternal supplementation of VitD
was not documented as this was not part of our study
protocol. Also, there was a 30 percent attrition rate in our
sample size from enrollment at birth to that at 6-8 weeks
secondary to inter hospital transfer.
To our knowledge, this study is the first showing a
trajectory of vitaminD status at three different time frames in
extremely preterm neonates. These results are generalizable
to other NICUs, as the cohort of patients is similar to
other neonatal intensive care units across Australia and New
Zealand, with similar VitD supplementation regimens in par-
enteral nutrition, vitamin supplementation, and fortification
of feeds. Given the significant proportion of pretermneonates
that are deficient/insufficient at birth with a proportion still
being deficient/insufficient at 3-4 weeks of life, there is a
potential role for VitD screening of all preterm neonates
at 3-4 weeks of life to ensure adequate VitD supplementa-
tion.
5. Conclusion
This study shows that VitD deficiency/insufficiency is com-
mon in mothers of preterm neonates and consequently in
preterm neonates at birth. Our current supplementation
practices ensure that the majority of neonates have sufficient
VitD levels at 6-8 weeks of life; however VitD supplementa-
tion inmothers and postnatally in preterm infants needs to be
individualized so as to normalize the serum VitD level in the
mothers during the third trimester as well as in the preterm
infants from the first few days of life.
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